Biology of childhood acute lymphoblastic leukemia

Journal of Pediatric Hematology/Oncology

Volumn 35, Issue 4, 2013, Pages 245-252

  Nigro, Luca Lo ^a  

^a Center of Pediatric Hematology Oncology   (Italy)

Author keywords

ALL; B lineage; Childhood; Molecular aberrations; Natural history

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CHILDHOOD CANCER; CHROMOSOME TRANSLOCATION; DISEASE PREDISPOSITION; DNA METHYLATION; DNA POLYMORPHISM; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENE LOCATION; GENE MUTATION; GENE REARRANGEMENT; GENE TARGETING; GENE THERAPY; GENE TRANSLOCATION; GENETIC ASSOCIATION; GENETIC EPIGENESIS; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HISTORY; HUMAN; IMMUNOSTIMULATION; MLL GENE; ONCOGENE; PATHOGENESIS; PRE B LYMPHOCYTE; PRE T LYMPHOCYTE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK REDUCTION; STEM CELL; SURVIVAL RATE; CHILD; GENETICS; PATHOLOGY;

CHILD; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

MLCS; MLOWN;

EID: 84878634330     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31828f8746     Document Type: Review

References (62)

1. Conter V, Aricò M, Basso G, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24:255-264.
2. Pui CH, Carroll W, Meshinchi S, et al. Biology, Risk stratification and therapy of Pediatric leukemias: an update. J Clin Oncol. 2011;29:551-565.
3. Wiemels J. Perspectives on the causes of childhood leukemia. Chem Biol Interact. 2012;196:59-67.
4. Mullighan C. Genomic profiling of B-progenitor acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2011; 24:489-503.
5. Linabery AM, Ross JA, Trends JA. in childhood cancer incidence in the US (1992-2004). Cancer. 2008;112:416-432.
6. Kaatsch P, Mergenthaler A. Incidence, time trends and regional variation of childhood leukaemia in Germany and Europe. Radiat Prot Dosimetry. 2008;132:107-113.
7. Greaves MF, Alexander FE. An infectious etiology for common acute lymphoblastic leukemia in childhood? Leukemia. 1993;7:349-360.
8. McHale CM, Wiemels JL, Zhang L, et al. Prenatal origin of TEL-AML1-positive acute lymphoblastic leukemia in children born in California. Genes Chromosomes Cancer. 2003;37:36-43.
9. Wiemels JL, Cazzaniga G, Daniotti M, et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet. 1999; 354:1499-1503.
10. Maia AT, Koechling J, Corbett R, et al. Protracted postnatal natural histories in childhood leukemia. Genes Chromosomes Cancer. 2004;39:335-340.
11. Almante Z, Samarani S, Iannello A, et al. Novel association between activating killer-cell immunoglobulin-like receptor genes and childhood leukemia. Blood. 2011;118:1323-1328.
12. Kinlen LJ. Epidemiological evidence for an infective basis in childhood leukaemia. Br J Cancer. 1995;71:1-5.
13. Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer. 2006;6:193-203.
14. Cazzaniga G, van Delft FW, Lo Nigro L, et al. Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukaemia. Blood. 2011;118:5559-5564.
15. Zuna J, Madzo J, Krejci O, et al. ETV6/RUNX1 (TEL/AML1) is a frequent prenatal first hit in childhood leukemia. Blood. 2011;117:368-369.
16. Mori H, Colman SM, Xiao Z, et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci USA. 2002; 99:8242-8247.
17. Greaves MT, Maia AT, Wiemels JL, et al. Leukemia in Twins: lessons in natural history. Blood. 2003;102:2321-2333.
18. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453:110-111.
19. den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10:125-134.
20. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470-480.
21. Carrol WL, Raetz EA. Clinical and laboratory biology of childhood acute lymphoblastic leukemia. J Pediatr. 2012; 160:10-18.
22. Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome: a review. Pediatr Hematol Oncol. 1999;9:139-149.
23. Forestier E, Izraeli S, Beverloo B, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood. 2008;111:1575-1583.
24. Hertzberg L, Vendramini E, Ganmore I, et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood. 2010;115:1006-1017.
25. Maloney KW, Carroll WL, Carroll AJ, et al. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. Blood. 2010;116:1045-1050.
26. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009;41:1243-1246.
27. Chen IM, Harvey RC, Mullighan CG, et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study. Blood. 2012;119:3512-3522.
28. Trevino LR, Yang W, French D, et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet. 2009;41:1001-1005.
29. Papaemmanuil E, Hosking FJ, Vijayakrishnan J, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet. 2009;41:1006-1010.
30. Ellinghaus E, Stanulla M, Richter G, et al. Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia. Leukemia. 2012;26: 902-909.
31. Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukemia. Br J Haematol. 2009;144:147-156.
32. Moorman AV, Ensor HM, Richards SM, et al. Prognostic effect of chromosomal abnormalities in childhood B-precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol. 2010;11:429-438.
33. Aricò M, Schrappe M, Hunger S, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosomepositive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol. 2010;28:4755-4761.
34. Meijerink JP, den Boer M, Pieters R. New genetic abnormalities and treatment response in acute lymphoblastic leukemia. Semin Hematol. 2009;46:16-23.
35. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481:157-163.
36. Lo Nigro L, Mirabile E, Tumino M, et al. Detection of CALM/AF10 fusion transcript does not predict a poor outcome in children with T-lineage acute lymphoblastic leukemia treated with AIEOP ALL 2000 protocol and subsequent modified 2000 study (R-2006). American Society of Hematology (ASH) 51st Annual Meeting 5-8 December, New Orleans [abstract 1578]. Blood. 2009;114:631.
37. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10:147-156.
38. Martelli AM, Evangelisti C, Chappel W, et al. Targeting the translational apparatus to improve leukemia therapy: roles of PI3K/PTEN/AKT/mTOR pathway. Leukemia. 2011;25: 1064-1079.
39. Lo Nigro L, Bonaccorso P, Tumino M, et al. Downregulation of mTOR and P70S6Kb2 in pediatric T-cell acute lymphoblastic leukemia (T-ALL) is correlated with a poor prognosis. American Society of Hematology (ASH) 53rd Annual Meeting, San Diego [abstract 2508]. Blood. 2011;116.
40. Aricò M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000;342: 998-1006.
41. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosomepositive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009;27:5175-5181.
42. Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370:240-250.
43. Meyer C, Kowarz E, Hofmann J, et al. New insights to the MLL recombinome of acute leukemias. Leukemia. 2009; 23:1490-1499.
44. Lo Nigro L, Valsecchi MG, Cazzaniga G, et al. Outcome of children (Non-Infant) with t(4;11) positive acute lymphoblastic leukemia treated with AIEOP-LLA 2000-R2006 protocols. 15th Congress of the European Hematology Association (EHA), Barcelona, June 10-13 [abstract 0617]. Haematologica. 2010;95(suppl 2):259.
45. Mullighan C. Genomic profiling of B-progenitor acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2011;24:489-503.
46. Fazio G, Palmi C, Rolink A, et al. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells. Cancer Res. 2008;68:181-189.
47. Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2009;106:9414-9418.
48. Rand V, Parker H, Russell LJ, et al. Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2011;117:6848-6855.
49. Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002;359: 1909-1915.
50. Van der Velden VH, Corral L, Valsecchi MG, et al. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia. 2009;23:1073-1079.
51. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30:41-47.
52. Trentin L, Giordan M, Dingermann T, et al. Two independent gene signatures in pediatric t(4;11) acute lymphoblastic leukemia patients. Eur J Haematol. 2009;85:406-419.
53. Bardini M, Galbiati M, Lettieri A, et al. Implementation of array based whole-genome high-resolution technologies confirms the absence of secondary copy-number alterations in MLL-AF4-positive infant ALL patients. Leukemia. 2011; 25:175-178.
54. Bernt K, Armstrong S. Targeting epigenetic programs in MLLrearranged leukemias. Hematology. 2011;354-360.
55. Bardini M, Wittmann L, Corral L, et al. In infant ALL with t(4;11)/MLL-AF4 multiple and phenotypically distinct CD19+ BM subsets initiate leukemia in NOD/SCID Mice. American Society of Hematology (ASH) 51st Annual Meeting [abstract 1432]. Blood. 2009;582:114.
56. Van Vlierberghe P, Pieters R, Beverloo HB, et al. Moleculargenetic insights in paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol. 2008;143:153-168.
57. Meijerink JP, den Boer M, Pieters R. New genetic abnormalities and treatment response in acute lymphoblastic leukemia. Semin Hematol. 2009;46:16-23.
58. Mullighan CG, Phillips LA, Sun X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008;322:1377-1380.
59. Szczepanski T, van der Velden VH, Waanders E, et al. Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition. J Clin Oncol. 2011; 29:1643-1649.
60. Lo Nigro L, Cazzaniga G, Di Cataldo A, et al. Clonal stability in children with acute lymphoblastic leukemia (ALL) who relapsed five or more years from diagnosis. Leukemia. 1999;13:190-195.
61. Mullighan CG, Zhang J, Kasper LH, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011;471:235-239.
62. Hogan LE, Meyer JA, Yang J, et al. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood. 2011;118:5218-5226.